FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Nishimura

Research Profile

Disorders

Melanoma

Anatomy

Chemicals & Drugs

Living Beings

Concepts & Ideas

Molecular Sequence Data

Physiology

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Jeffrey A Mosenson; JD Nieland; Michael I Nishimura; Andreas Overbeck; Andrew Zloza; Shikhar Mehrotra; Ahmad Alamiri; Steven D Bines; Cecele J Denman; Jonathan M Eby; Elizabeth Garrett-Mayer; Jose A. Guevara-Patino; Claudia Hernandez; Erica J Huelsmann; Tasha Hughes; Howard L Kaufman; Frederick J Kohlhapp; Previn Kumar; Andrew T Lacek; I Caroline Le Poole
Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
Shikhar Mehrotra; Anuradha K Murali; Osama Naga; Håkan Norell; Georgiana Onicescu; Natali D Spivey; Amir A Al-Khami; David J Cole; Claudia Diaz; Jonathan M Eby; Elizabeth Garrett-Mayer; Shahid Husain; Jared Klarquist; I Caroline Le Poole; Mingli Li; Gretchen E Lyons; Telma Martins da Palma; Michael I Nishimura
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.
Andrew Zloza; Michael Christopher Jagoda; Gretchen E Lyons; Michael C Graves; Frederick J Kohlhapp; Jeremy A O'Sullivan; Andrew T Lacek; Michael I Nishimura; José A Guevara-Patiño
CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Nishimura (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jeffrey A Mosenson; JD Nieland; Michael I Nishimura; Andreas Overbeck; Andrew Zloza; Shikhar Mehrotra; Ahmad Alamiri; Steven D Bines; Cecele J Denman; Jonathan M Eby; Elizabeth Garrett-Mayer; Jose A. Guevara-Patino; Claudia Hernandez; Erica J Huelsmann; Tasha Hughes; Howard L Kaufman; Frederick J Kohlhapp; Previn Kumar; Andrew T Lacek; I Caroline Le Poole
Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
Science translational medicine 2013;5(174):174ra28.
2012: Shikhar Mehrotra; Anuradha K Murali; Osama Naga; Håkan Norell; Georgiana Onicescu; Natali D Spivey; Amir A Al-Khami; David J Cole; Claudia Diaz; Jonathan M Eby; Elizabeth Garrett-Mayer; Shahid Husain; Jared Klarquist; I Caroline Le Poole; Mingli Li; Gretchen E Lyons; Telma Martins da Palma; Michael I Nishimura
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(4):1627-38.
2011: Andrew Zloza; Michael Christopher Jagoda; Gretchen E Lyons; Michael C Graves; Frederick J Kohlhapp; Jeremy A O'Sullivan; Andrew T Lacek; Michael I Nishimura; José A Guevara-Patiño
CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression.
Cancer immunology, immunotherapy : CII 2011;60(2):291-7.
2011: Kousaku Mimura; Takashi Ando; Isabel Poschke; Dimitrios Mougiakakos; C Christian Johansson; Jiro Ichikawa; Riki Okita; Michael I Nishimura; Diana Handke; Nancy Krug; Aniruddha Choudhury; Barbara Seliger; Rolf Kiessling
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
International journal of cancer. Journal international du cancer 2011;128(2):390-401.
2010: Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.
Cancer immunology, immunotherapy : CII 2010;59(6):851-62.
2010: Jared Klarquist; Cecele J Denman; Claudia Hernandez; Derek A Wainwright; Derek J Wainwright; Faith M Strickland; Andreas Overbeck; Shikar Mehrotra; Michael I Nishimura; I Caroline Le Poole
Reduced skin homing by functional Treg in vitiligo.
Pigment cell & melanoma research 2010;23(2):276-86.
2010: Yi Zhang; Yeuying Liu; Kelly M Moxley; Lucy Golden-Mason; Michael G Hughes; Tongxin Liu; Mirjam H M Heemskerk; Hugo R Rosen; Michael I Nishimura
Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity.
PLoS pathogens 2010;6(7):e1001018.
2009: Håkan Norell; Telma Martins da Palma; Aaron Lesher; Navtej Kaur; Meenal Mehrotra; Osama Naga; Natalie Spivey; Seye Olafimihan; Nitya G Chakraborty; Christina Voelkel Johnson; Michael I Nishimura; Bijay Mukherji; Shikhar Mehrotra
Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.
Cancer research 2009;69(15):6282-9.
2009: Simon Voelkl; Tamson V Moore; Michael Rehli; Michael I Nishimura; Andreas Mackensen; Karin Fischer
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
Cancer immunology, immunotherapy : CII 2009;58(5):709-18.
2009: Tamson V Moore; Gretchen E Lyons; Natasha Brasic; Jeffrey J Roszkowski; Simon Voelkl; Andreas Mackensen; W Martin Kast; I Caroline Le Poole; Michael I Nishimura
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Cancer immunology, immunotherapy : CII 2009;58(5):719-28.
2009: M P Rubinstein; Mohamed L Salem; A N Kadima; Christophe L Nguyen; W E Gillanders; Michael I Nishimura; David J Cole
Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo.
Cancer gene therapy 2009;16(2):171-83.
2009: Claudia Diaz; Mohamed L Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto Montero
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
Cancer immunology, immunotherapy : CII 2009;58(1):49-59.
2008: Takashi Ando; Kousaku Mimura; C Christian Johansson; Mikael G Hanson; Dimitrios Mougiakakos; Charlotte Larsson; Telma Martins da Palma; Daiju Sakurai; Håkan Norell; Mingli Li; Michael I Nishimura; Rolf Kiessling
Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(12):8382-90.
2008: F Nakajima; Michael I Nishimura; S Hashimoto; H Okazaki; K Tadokoro
Role of anti-Nak(a) antibody, monocytes and platelets in the development of transfusion-related acute lung injury.
Vox sanguinis 2008;95(4):318-23.
2007: Michael I Nishimura; S Hashimoto; M Satake; H Okazaki; K Tadokoro
Interference with TRALI-causing anti-HLA DR alloantibody induction of human pulmonary microvascular endothelial cell injury by purified soluble HLA DR.
Vox sanguinis 2007;93(1):78-82.
2007: Lu Deng; Ries J Langley; Patrick Brown; Gang Xu; Leslie Teng; Qian Wang; Monica I Gonzales; Glenda G Callender; Michael I Nishimura; Suzanne Topalian; Roy A Mariuzza
Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor.
Nature immunology 2007;8(4):398-408.
2007: Mark D McKee; Allesandro Fichera; Michael I Nishimura
T cell immunotherapy.
Frontiers in bioscience : a journal and virtual library 2007;12():919-32.
2006: Gretchen E Lyons; Tamson Moore; Natasha Brasic; Mingli Li; Jeffrey J Roszkowski; Michael I Nishimura
Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells.
Cancer research 2006;66(23):11455-61.
2006: Gretchen E Lyons; Jeffrey J Roszkowski; Stephen Man; Cassian Yee; W Martin Kast; Michael I Nishimura
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells.
Cancer immunology, immunotherapy : CII 2006;55(9):1142-50.
2006: Kepa Oyarbide-Valencia; Jasper G van den Boorn; Cecele J Denman; Mingli Li; Jeremy M Carlson; Claudia Hernandez; Michael I Nishimura; Pranab K Das; Rosalie M Luiten; I Caroline Le Poole
Therapeutic implications of autoimmune vitiligo T cells.
Autoimmunity reviews 2006;5(7):486-92.
2006: Barbara L F Kaplan; Håkan Norell; Glenda G Callender; Tomas Ohlum; Rolf Kiessling; Michael I Nishimura
Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.
Cancer immunology, immunotherapy : CII 2006;55(6):653-62.
2006: Glenda G Callender; Hugo Rosen; Jeffrey J Roszkowski; Gretchen E Lyons; Mingli Li; Tamson Moore; Natasha Brasic; Mark D McKee; Michael I Nishimura
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition.
Hepatology (Baltimore, Md.) 2006;43(5):973-81.
2006: Lone Duval; Henrik Schmidt; Keld Kaltoft; Kirsten Fode; Jens Jorgen Jensen; Steen Mellerup Sorensen; Michael I Nishimura; Hans von der Maase
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1229-36.
2005: Shin-Ichiro Fujii; Michael I Nishimura; Michael T Lotze
Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells.
Cancer science 2005;96(12):897-902.
2005: Mark D McKee; Jeffrey J Roszkowski; Michael I Nishimura
T cell avidity and tumor recognition: implications and therapeutic strategies.
Journal of translational medicine 2005;3():35.
2005: Licheng Wu; Oscar Estrada; Olga Zaborina; Manjeet Bains; Le Shen; Jonathan E Kohler; Nachiket Patel; Mark W Musch; Eugene B Chang; Yang-Xin Fu; Michael A Jacobs; Michael I Nishimura; Robert E W Hancock; Jerrold R Turner; John C Alverdy
Recognition of host immune activation by Pseudomonas aeruginosa.
Science (New York, N.Y.) 2005;309(5735):774-7.
2005: Barbara L F Kaplan; Tamson V Moore; Karin Schreiber; Glenda G Callender; Hans Schreiber; Michael I Nishimura
A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity.
Cancer letters 2005;224(1):153-66.
2005: Jeffrey J Roszkowski; Gretchen E Lyons; W Martin Kast; Cassian Yee; Koen van Besien; Michael I Nishimura
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Cancer research 2005;65(4):1570-6.
2005: Michael I Nishimura; Jeffrey J Roszkowski; Tamson V Moore; Natasha Brasic; Mark D McKee; Timothy M Clay
Antigen recognition and T-cell biology.
Cancer treatment and research 2005;123():37-59.
2004: Hugo Rosen; David J Hinrichs; Rachel L Leistikow; Glenda G Callender; Anne M Wertheimer; Michael I Nishimura; David M Lewinsohn
Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(9):5355-9.
2004: Elena N Klyushnenkova; Sathibalan Ponniah; Alejandro Rodriguez; James Kodak; Dean L Mann; Alexander Langerman; Michael I Nishimura; Richard B Alexander
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(2):136-46.
2003: Kyung-Mi Lee; Sadhna Bhawan; Takashi Majima; Hairong Wei; Michael I Nishimura; Hideo Yagita; Vinay Kumar
Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(10):4881-5.
2003: Barbara L F Kaplan; David C Yu; Timothy M Clay; Michael I Nishimura
Redirecting T lymphocyte specificity using T cell receptor genes.
International reviews of immunology 2003;22(3-4):229-53.
2003: Jeffrey J Roszkowski; David C Yu; Mark P Rubinstein; Mark D McKee; David J Cole; Michael I Nishimura
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(5):2582-9.
2003: Mark P Rubinstein; Andre N Kadima; Mohamed L Salem; Christophe L Nguyen; William E Gillanders; Michael I Nishimura; David J Cole
Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(3):1209-17.
2003: Gretchen L Eiben; Diane M Da Silva; Steven C Fausch; I Caroline Le Poole; Michael I Nishimura; W Martin Kast
Cervical cancer vaccines: recent advances in HPV research.
Viral immunology 2003;16(2):111-21.
2003: Timothy M Clay; Michael I Nishimura
Retroviral transfer of T-cell receptor genes into human peripheral blood lymphocytes.
Methods in molecular biology (Clifton, N.J.) 2003;215():227-34.
2002: Michael T Spiotto; Ping Yu; Donald A Rowley; Michael I Nishimura; Stephen C Meredith; Thomas F Gajewski; Yang-Xin Fu; Hans Schreiber
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.
Immunity 2002;17(6):737-47.
2001: Mark E Dudley; John R Wunderlich; Michael I Nishimura; D Yu; James C Yang; Suzanne Topalian; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Richard M Sherry; Susan F Leitman; STEVEN ROSENBERG
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(4):363-73.
2001: Rimas J Orentas; S J Roskopf; G P Nolan; Michael I Nishimura
Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
Clinical immunology (Orlando, Fla.) 2001;98(2):220-8.
2000: MD McKee; Timothy M Clay; R A Diamond; STEVEN ROSENBERG; Michael I Nishimura
Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):419-29.
2000: Andrea Ladányi; Michael I Nishimura; STEVEN ROSENBERG; James C Yang
Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(1):36-47.
1999: Michael I Nishimura; Dody Avichezer; Mary Custer; C S Lee; Chi Chen; Maria R Parkhurst; R A Diamond; Paul F Robbins; Douglas J Schwartzentruber; STEVEN ROSENBERG
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Cancer research 1999;59(24):6230-8.
1999: Franck Housseau; Robert K Bright; T Simonis; Michael I Nishimura; Suzanne Topalian
Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(11):6330-7.
1999: Mark E Dudley; Michael I Nishimura; A K Holt; STEVEN ROSENBERG
Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(4):288-98.
1999: Timothy M Clay; Mary Custer; J Sachs; Patrick Hwu; STEVEN ROSENBERG; Michael I Nishimura
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):507-13.
1999: MD McKee; Timothy M Clay; STEVEN ROSENBERG; Michael I Nishimura
Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(2):93-102.
1999: Rembert Pieper; Robert E Christian; Monica I Gonzales; Michael I Nishimura; Ghanshyam Gupta; Robert E Settlage; Jeffrey Shabanowitz; STEVEN ROSENBERG; Donald F Hunt; Suzanne Topalian
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.
The Journal of experimental medicine 1999;189(5):757-66.
1999: Timothy M Clay; Mary Custer; MD McKee; Maria R Parkhurst; Paul F Robbins; Kimberly F Kerstann; John R Wunderlich; STEVEN ROSENBERG; Michael I Nishimura
Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1749-55.
1999: Timothy M Clay; Mary Custer; Paul J Spiess; Michael I Nishimura
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
Pathology oncology research : POR 1999;5(1):3-15.
1998: Michael I Nishimura; Mary Custer; Susan L Schwarz; Linda L Parker; Arnold Mixon; Timothy M Clay; J R Yannelli; STEVEN ROSENBERG
T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(5):352-62.
1997: David J Cole; M C Wilson; L Rivoltini; Mary Custer; Michael I Nishimura
T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cancer research 1997;57(23):5320-7.
1997: joel shilyansky; James C Yang; Mary Custer; Paul J Spiess; Arnold Mixon; David J Cole; J J Mulé; STEVEN ROSENBERG; Michael I Nishimura
Identification of a T-cell receptor from a therapeutic murine T-cell clone.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):247-55.
1997: Y Zhai; James C Yang; Paul J Spiess; Michael I Nishimura; Willem W Overwijk; B Roberts; Nicholas P Restifo; STEVEN ROSENBERG
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):15-25.
1996: DJ Loftus; Chiara Castelli; Timothy M Clay; Paola Squarcina; Francesco M Marincola; Michael I Nishimura; Giorgio Parmiani; Ettore Appella; Licia Rivoltini
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
The Journal of experimental medicine 1996;184(2):647-57.
1996: R S Chamberlain; MW Carroll; Vincenzo Bronte; Patrick Hwu; S Warren; J C Yang; Michael I Nishimura; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
Cancer research 1996;56(12):2832-6.
1996: Michael I Nishimura; S Uchida; S Mitsunaga; Katsushi Tokunaga; Kenji Tadokoro; Takeo Juji
Evidence of involvement of cytotoxic antibodies directed against patients's HLA class II produced by transfused donor-derived B cells in post-transfusion graft-versus-host disease.
British journal of haematology 1996;92(4):1011-3.
1996: Yoshihide Ishikawa; Katsushi Tokunaga; Harunari Tanaka; Michael I Nishimura; M Muraoka; Y Fujii; T Akaza; Kenji Tadokoro; Takeo Juji
HLA-A null allele with a stop codon, HLA-A*0215N, identified in a homozygous state in a healthy adult.
Immunogenetics 1996;43(1-2):1-5.
1995: J R Yannelli; S McConnell; L Parker; Michael I Nishimura; P Robbins; J Yang; Mona El-Gamil; Y Kawakami
Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(4):263-71.
1995: B J McCabe; Kari R Irvine; Michael I Nishimura; J C Yang; Paul J Spiess; EP Shulman; STEVEN ROSENBERG; Nicholas P Restifo
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
Cancer research 1995;55(8):1741-7.
1995: L Lin; K Tokunaga; Yoshihide Ishikawa; Katsushi Tokunaga; Koichi Kashiwase; Makoto Bannai; Michael I Nishimura; S Kuwata; T Akaza; Kenji Tadokoro
A new member of the HLA-B40 family of alleles, B*4007, coding for B'FU' serological specificity.
Tissue antigens 1995;45(4):276-9.
1995: M Takanashi; Michael I Nishimura; K Tadokoro; T Juji
Graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets.
Transfusion 1995;35(3):276-7.
1995: David J Cole; D P Weil; joel shilyansky; Mary Custer; Y Kawakami; STEVEN ROSENBERG; Michael I Nishimura
Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen.
Cancer research 1995;55(4):748-52.
1994: David J Cole; D P Weil; Peter Shamamian; Licia Rivoltini; Y Kawakami; Suzanne Topalian; C Jennings; S Eliyahu; STEVEN ROSENBERG; Michael I Nishimura
Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cancer research 1994;54(20):5265-8.
1994: Michael I Nishimura; Y Kawakami; P Charmley; B O'Neil; joel shilyansky; J R Yannelli; STEVEN ROSENBERG; Leroy Hood
T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(2):85-94.
1994: joel shilyansky; Michael I Nishimura; J R Yannelli; Y Kawakami; L S Jacknin; P Charmley; STEVEN ROSENBERG
T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(7):2829-33.
1993: Y Ito; M Nieda; Y Uchigata; Michael I Nishimura; K Tokunaga; S Kuwata; Fumiya Obata; Kenji Tadokoro; Y Hirata; Y Omori
Recognition of human insulin in the context of HLA-DRB1*0406 products by T cells of insulin autoimmune syndrome patients and healthy donors.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(10):5770-6.
1993: Y Kawakami; Michael I Nishimura; Nicholas P Restifo; Suzanne Topalian; Bert O Neil; joel shilyansky; J R Yannelli; STEVEN ROSENBERG
T-cell recognition of human melanoma antigens.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):88-93.
1993: Michael I Nishimura; T Akaza; Y Mitomi; M Nieda; M Minami; Takeo Juji
Establishment of human minor histocompatibility antigen-specific cytotoxic T cell clones restricted by HLA-DR9.
Transplantation 1993;55(5):1181-6.
1991: Michael I Nishimura; Suzanne Ostrand-Rosenberg
Mouse Hepa-1 tumor is rejected by H-2Db-restricted CTL despite decreased MHC class I antigen expression.
Cellular immunology 1991;136(2):414-24.
1990: Suzanne Ostrand-Rosenberg; G A Cole; Michael I Nishimura; Virginia K Clements
Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host.
Cellular immunology 1990;128(1):152-64.
1988: Michael I Nishimura; I Stroynowski; L Hood; Suzanne Ostrand-Rosenberg
H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(12):4403-9.